scholarly journals Serial Changes in Expression of Proteins in Response to Neoadjuvant Chemotherapy in Breast Cancer

10.5772/54979 ◽  
2013 ◽  
Author(s):  
Daniel Chan ◽  
Soo-Chin Lee
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Response To Neoadjuvant Chemotherapy

64P Mammographic density to predict response to neoadjuvant chemotherapy for breast cancer

2021 ◽  
Vol 32 ◽  
pp. S49
Author(s):  
S. Di Cosimo ◽  
C. Depretto ◽  
R. Miceli ◽  
P. Baili ◽  
M. Sant ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Mammographic Density ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer.

2021 ◽  
Author(s):  
Sophie C. Hagenaars ◽  
Stefanie Groot ◽  
Danielle Cohen ◽  
Tim J.A. Dekker ◽  
Ayoub Charehbili ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Tumor Stroma ◽  
Pathological Response ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi‐institutional study

2020 ◽  
Vol 9 (16) ◽  
pp. 5798-5806
Author(s):  
Daniel DiCenzo ◽  
Karina Quiaoit ◽  
Kashuf Fatima ◽  
Divya Bhardwaj ◽  
Lakshmanan Sannachi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Quantitative Ultrasound ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Response To Neoadjuvant Chemotherapy

Predictive Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Monocentric Study of Salah Azaiez Institute

2020 ◽  
Vol 46 (2) ◽  
pp. e37-e38
Author(s):  
Imen Zawati ◽  
Sabrine Boukhris ◽  
Marwa Manai ◽  
Aida Goucha ◽  
Ilhem Bettaieb ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Predictive Markers ◽  
Response To Neoadjuvant Chemotherapy

Tumour-stroma ratio is associated with Miller-Payne grading system and pathological response to neoadjuvant chemotherapy in HER2-negative breast cancer

2021 ◽  
Vol 47 (2) ◽  
pp. e18-e19
Author(s):  
Sophie Hagenaars ◽  
Stefanie de Groot ◽  
Danielle Cohen ◽  
Tim Dekker ◽  
Marjolijn Duijm-de Carpentier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Pathological Response ◽  
Grading System ◽  
Tumour Stroma ◽  
Response To Neoadjuvant Chemotherapy

Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy

2012 ◽  
Vol 324 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Ryo Tsunashima ◽  
Yasuto Naoi ◽  
Kazuki Kishi ◽  
Yosuke Baba ◽  
Atsushi Shimomura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
High Risk ◽  
Neoadjuvant Chemotherapy ◽  
Estrogen Receptor Positive ◽  
Response To Neoadjuvant Chemotherapy ◽  
Positive Breast Cancer

scholarly journals Relationship Between Obesity and Pathologic Response to Neoadjuvant Chemotherapy Among Women With Operable Breast Cancer

2008 ◽  
Vol 26 (25) ◽  
pp. 4072-4077 ◽  
Author(s):  
Jennifer K. Litton ◽  
Ana M. Gonzalez-Angulo ◽  
Carla L. Warneke ◽  
Aman U. Buzdar ◽  
Shu-Wan Kau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Pathologic Complete Response ◽  
Operable Breast Cancer ◽  
Obese Patients ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Response To Neoadjuvant Chemotherapy

Purpose To understand the mechanism through which obesity in breast cancer patients is associated with poorer outcome, we evaluated body mass index (BMI) and response to neoadjuvant chemotherapy (NC) in women with operable breast cancer. Patients and Methods From May 1990 to July 2004, 1,169 patients were diagnosed with invasive breast cancer at M. D. Anderson Cancer Center and received NC before surgery. Patients were categorized as obese (BMI ≥ 30 kg/m2), overweight (BMI of 25 to < 30 kg/m2), or normal/underweight (BMI < 25 kg/m2). Logistic regression was used to examine associations between BMI and pathologic complete response (pCR). Breast cancer–specific, progression-free, and overall survival times were examined using the Kaplan-Meier method and Cox proportional hazards regression analysis. All statistical tests were two-sided. Results Median age was 50 years; 30% of patients were obese, 32% were overweight, and 38% were normal or underweight. In multivariate analysis, there was no significant difference in pCR for obese compared with normal weight patients (odds ratio [OR] = 0.78; 95% CI, 0.49 to 1.26). Overweight and the combination of overweight and obese patients were significantly less likely to have a pCR (OR = 0.59; 95% CI, 0.37 to 0.95; and OR = 0.67; 95% CI, 0.45 to 0.99, respectively). Obese patients were more likely to have hormone-negative tumors (P < .01), stage III tumors (P < .01), and worse overall survival (P = .006) at a median follow-up time of 4.1 years. Conclusion Higher BMI was associated with worse pCR to NC. In addition, its association with worse overall survival suggests that greater attention should be focused on this risk factor to optimize the care of breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document